Abstract
High global expenditure on out-of-label-date drugs, along with safety concerns associated with the accumulation of degradation impurities, justify the need for stability profiling. In this article, a comprehensive study on the solid-state stability of ramipril (RAM) was performed via isothermal methods under stress conditions. A validated stability-indicating HPLC protocol was used. The effects of various factors on the rate of RAM degradation were investigated, including: temperature, relative air humidity (RH), excipients (talc, starch, methylcellulose and hydroxypropyl methylcellulose), mode of tablet storage, and immediate packaging. The degradation impurities were also identified by HPLC–MS. It was found that RAM was unstable, and temperature accelerated its degradation. RAM was also vulnerable to RH changes, suggesting that it must be protected from moisture. The reaction followed first-order kinetics. The studied excipients stabilized RAM as a pure substance. The tableting process deteriorated its stability, explaining the need for appropriate immediate packaging. RAM in the form of tablets must be stored in blisters, and it cannot be crushed into two halves. The degradation impurities were ramiprilat and the diketopiperazine derivative.
Funder
Greater Poland Cancer Center
Poznan University of Medical Sciences
Reference25 articles.
1. A systematic review of the stability of finished pharmaceutical products and drug substances beyond their labeled expiry dates
2. Stability testing of pharmaceutical products;Bajaj;Int. J. Appl. Pharm. Sci. Res.,2012
3. The European Medicines Agency’s Scientific Guidelines on the Stability of Drug Substances and Drug Products Help Medicine Developers Prepare Marketing Authorisation Applications for Human Medicineshttps://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/quality/quality-stability
4. The European Medicines Agency’s Scientific Guidelines on Impurities in Drug Products and Drug Substances Help Medicine Developers Prepare Marketing Authorisation Applications for Human Medicineshttps://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/quality/quality-impurities
5. ICH M7 Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Riskhttps://www.ema.europa.eu/documents/scientific-guideline/ich-guideline-m7r1-assessment-control-dna-reactive-mutagenic-impurities-pharmaceuticals-limit_en.pdf
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献